Skip to Content

'
Farshid Dayyani, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1374
Houston 77030
Room Number: CPB7.3510
Phone: 713/563-4195

Education & Training

Degree-Granting Education

2002 Ludwig-Maximilians-Universitaet, Munich, Germany, MD, Magna Cum Laude, Medicine / Immunology

Postgraduate Training

7/2008-6/2011 Clinical Fellowship, University of Texas, MD Anderson Cancer Center, Houston, TX
6/2006-6/2008 Clinical Residency, Internal Medicine, Harvard University, Beth Israel Deaconess Medical Center, Boston, MA
1/2004-5/2006 Research Fellowship, Cancer Biology, Harvard University, Massachusetts General Hospital, Boston, MA
6/2002-12/2003 Clinical Internship, Oncology, Ludwig-Maximilians-Universitaet, University Hospital, Munich, Germany

Experience/Service

Academic Appointments

Instructor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2011-4/2012

Honors and Awards

2011 2011 ASCO Cancer Foundation Merit Award, Genitourinary Cancers Symposium, American Society of Clinical Oncology
2011 Achievement in Basic Science Fellowship Award 2011, The University of Texas MD Anderson Cancer Center
2010 3rd Poster Prize Symposia on Cancer Research, Personalized Cancer Therapy and Prevention
2010 ASCO Young Investigator Award, American Society of Clinical Oncology
2010 MD Anderson Cancer Center Trainee Excellence Award, The University of Texas MD Anderson Cancer Center
2010 Texas Society of Medical Oncology Annual Meeting Research Award, Texas Society of Medical Oncology
2009 AACR Workshop Methods in Clinical Cancer Research, Vail, CO, American Association for Cancer Research
2009 AACR Workshop Molecular Biology in Oncology, American Association for Cancer Research
2009 MD Anderson Cancer Center Clifton D. Howe Award for Clinical Excellence, The University of Texas MD Anderson Cancer Center
2009 Texas Society of Medical Oncology Annual Meeting Research Award, Texas Society of Medical Oncology

Professional Memberships

ASCO
Associate Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. In Press.
2. Frankenberger M, Hofer T, Marei A, Dayyani F, Schewe S, Strasser C, Adraihim A, Stanzel F, Lang R, Hoffman R, Prazeres de Costa O, Buch T, Ziegler-Heitbrock L. Transcript profiling of CD16-positive monocytes reveals a unique molecular finger rprint. Eur J Immunol. In Press.
3. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 20(12):1677-84, 12/2011. e-Pub 10/28/2011. PMID: 22035268.
4. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst 103(22):1665-1675, 11/16/2011. e-Pub 9/13/2011. PMID: 21917607.
5. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol 86(7):546-9, 7/2011. e-Pub 4/20/2011. PMID: 21509801.
6. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128(11):2545-61, 6/1/2011. e-Pub 3/28/2011. PMCID: PMC3082284.
7. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 117(1):110-5, 1/1/2011. e-Pub 8/27/2010. PMID: 20803607.
8. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116(9):2174-9, 5/1/2010. PMID: 20162709.
9. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2:15, 2010. e-Pub 6/29/2010. PMCID: PMC2908081.
10. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman's disease. Am J Hematol 83(6):498-503, 6/2008. PMID: 18260115.
11. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 111(9):4716-22, 5/1/2008. e-Pub 2/25/2008. PMCID: PMC2343601.
12. Dayyani F, Wang J, Yeh JR, Ahn EY, Tobey E, Zhang DE, Bernstein ID, Peterson RT, Sweetser DA. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood 111(8):4338-47, 4/15/2008. e-Pub 2/7/2008. PMCID: PMC2288729.
13. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ. Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci 334(4):317-9, 10/2007. PMID: 18030193.
14. Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB. Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. Genes Chromosomes Cancer 44(3):279-91, 11/2005. PMID: 16015647.
15. Schiemann U, Dayyani V, Müller-Lisse UG, Siebeck M. [Aerobilia as an initial sign of a cholecystoduodenal fistula--a case report]. MMW Fortschr Med 146(35-36):39-40, 9/2/2004. PMID: 15540538.
16. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104(6):1825-32, 9/15/2004. e-Pub 5/25/2004. PMID: 15161667.
17. Dayyani F, Joeinig A, Ziegler-Heitbrock L, Schmidmaier R, Straka C, Emmerich B, Meinhardt G. Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma. J Leukoc Biol 75(2):207-13, 2/2004. e-Pub 10/23/2003. PMID: 14576364.
18. Then Bergh F, Dayyani F, Ziegler-Heitbrock L. Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol 146(1-2):176-88, 1/2004. PMID: 14698861.
19. Meinhardt G, Dayyani F, Jahrsdörfer B, Baumgart J, Emmerich B, Schmidmaier R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 122(6):892-9, 9/2003. PMID: 12956758.
20. Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler-Heitbrock L. Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J Leukoc Biol 74(1):33-9, 7/2003. PMID: 12832440.
21. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 168(7):3536-42, 4/1/2002. PMID: 11907116.
22. Steppich B, Dayyani F, Gruber R, Lorenz R, Mack M, Ziegler-Heitbrock HW. Selective mobilization of CD14(+)CD16(+) monocytes by exercise. Am J Physiol Cell Physiol 279(3):C578-86, 9/2000. PMID: 10942707.

Abstracts
1. Dayyani F, Pettaway C, Kamat AM, Munsell M, Pagliaro LC. Advanced urethral carcinomas: A retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy - The M. D. Anderson experience. 2012 Genitourinary Cancers Symposium(330), 2012.
2. Dayyani F, Munsell M, Siefker-Radtke AO. Incidence of peritoneal carcinomatosis in recurrent plasmacytoid ruothelial carcinomas (PUC) of the bladder: A retrospective analysis of patient outcomes at M. D. Anderson Cancer Center (MDACC). 2012 Genitourinary Cancers Symposium:297, 2012.
3. Dayyani F, Parikh N, Song JH, Araujo JC, Carboni JM, Gottardis MM, Trudel GC, Logoehttis C, Gallick GE. Inhibition of Src and insulin/insulin-like growth factor-1 receptor (IR/IGF-1R) on tumors and bone turnover in prostate cancer (PCa) models in vivo compared with inhibition of either kinase alone. 2012 Genitourinary CAncers Symposium:61, 2012.
4. Dayyani F, Parikh N, Song JH, Araujo JC, Carboni JM, Gottardis MM, Trudel GC, Logothetis C, Gallick GE. Effect of dual inhibition of the Src and insulin-like growth factor-1 receptor (IGF-1R) pathways on antitumor effects in prostate cancer (PCa). J Clin Oncol 29(Suppl 7):21, 2011.
5. Dayyani F. . Correlation of bone markers, serum cytokine and dasatinib levels, and response to combination therapy with dasatinib and docetaxel in patients with castration-resistant progressive prostate cancer. Texas Society of Medical Oncology Annual Meeting, 2010.
6. Dayyani F, Gallick GE, Trudel GC, Logothetis CJ, Araujo J. Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC). J Clin Oncol 28(15s):4665, 2010.
7. Dayyani F, Trudel G, Gallick G, Logothetis C, Araujo J. Decline in bone markers and response to combination therapy with dasatinib and docetaxel in patients with castration-resistant progressive prostate cancer (CRPC). 2010 Genitourinary Cancers Symposium, 2010.
8. Dayyani F, Schellhorn Mougalian S, Naqvi K, Ravandi F, Cortes J, Jabbour E, Faderl S, Wierda W, Thomas D, O’Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Intracranial Hemorrhage (ICH) in Patients (Pts) Presenting with myeloid leukemia to a tertiary care center. Blood 114:2170, 2010.
9. Jianfeng Wang J, Dayyani F, Brynzka C, Sweetser D. TLEs Regulate Myeloid Proliferation and Differentiation In Association with Modulation of NF-κB and Wnt Signaling. Blood 114:2170, 2010.
10. Dayyani F, Etzel C, Liu M, Ho C, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus on cancer risk and overall survival in head and neck squamous cell carcinoma. J Clin Oncol 27(15s):6080, 2009.
11. Dayyani F. Meta-analysis of the impact of human papillomavirus on cancer risk and overall survival in head and neck squamous cell carcinoma. Texas Society of Medical Oncology Annual Meeting, 2009.
12. Dayyani F, Kantarjian H, O’Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) With or Without Arsenic Trioxide (ATO) as a Component of Frontline Therapy. Blood 113:1050, 2009.
13. Dayyani F, Conley AP, Pierce S, Strom S, Stevenson W, Borthakur G, Kantarjian H, Garcia-Manero G. Disease-Related Mortality in Patients with Lower-Risk Myelodysplastic Syndrome (MDS). Blood 112:5073, 2008.
14. Wang J, Dayyani F, Brynczka C, Sweetser DA. Groucho/TLE Corepressors Regulate Myeloid Differentiation and Size of the Stem Cell/Progenitor Population. Blood 112:1396, 2008.
15. Sweetser DA, Dayyani F, Wang J, Zhang Y, Zaidi T. The Groucho Corepressors, TLE1 and TLE4, Are Candidate Del(9q) AML Tumor Suppressor Genes That Can Complement AML1-ETO. Blood 108:1406, 2006.
16. Dayyani F, Zhang Y, Zaidi ST, Sweetser DA. TLE Corepressors as Novel Candidate AML Tumor Suppressor Genes That Regulate Wnt Signaling, Cell Cycle Progression, and Myeloid Differentiation. Blood 106:1601, 2005.
17. Dayyani F. CD14+CD16+ monocytes in autologous peripheral blood stem cell transplantation (APBSCT). Meeting of the European Macrophage and Dendritic Cell Society, 2003.

Book Chapters
1. Dayyani F and Jonasch E. “Chemotherapy (and targeted therapies)” in Part IV on Imaging of Interventional Therapies in Section 5 on Renal Cell. In: Image-guided Cancer Therapy: A Multiple-disciplinary Approach. Ed(s) William N. McMullen, Dr. Yuman Fong, Dr. Damian Dupuy, Dr. Chul S. Ha and Dr. Jordan Berlin, 2011.
2. Dayyani F and Tannir N. Targeted Therapies in Genitourinary Malignancies. In: Targeted Therapy for Solid Tumors and Hematologic Malignancies. Ed(s) Cataldo, Gibbons, Quintas-Cardama, 2011.

Last updated: 9/24/2012